文献速递临床免疫分子诊断质量管理与危急值

ARIC研究中不同平台蛋白质组测量的比较

Comparison of Proteomic Measurements Across Platforms in the Atherosclerosis Risk in Communities (ARIC) Study.
PubMed 文献 · Clin Chem · 2023-01-01

该研究在ARIC队列中比较了基于适配体的SomaScan v4与邻近延伸免疫分析OLINK Proseek在427名参与者中的蛋白质测量相关性,并对比了SomaScan与靶向免疫分析在110名参与者中的18种蛋白质。结果显示不同平台间蛋白质测量相关性存在差异,平均相关系数r=0.46,仅19%的蛋白质比较r≥0.8;与靶向免疫分析比较中,6种蛋白质相关性好,2种中等,10种差。

要点

  • SomaScan与OLINK平台间蛋白质测量相关性差异大,平均r=0.46。
  • SomaScan与靶向免疫分析比较中,仅6/18种蛋白质相关性好(r≥0.8)。
  • 蛋白质定量研究的设计与解释需考虑测量技术间的变异。

核心结论

  • 基于适配体和邻近延伸免疫分析方法对多种蛋白质的定量测量存在变异,约一半显示良好或中等相关性,约一半相关性差。

研究设计与样本

  • 在427名ARIC研究参与者(Visit 5, 2011-2013)中比较SomaScan v4和OLINK Proseek v5003的蛋白质测量,并在110名参与者(55例心血管疾病病例,55例对照)中比较18种SomaScan蛋白质与靶向免疫分析。

主要发现

  • SomaScan与OLink平台间有417个蛋白质比较(366种独特蛋白质),平均相关系数r=0.46(范围-0.21至0.97),其中79个(19%)比较r≥0.8。
  • SomaScan与靶向免疫分析比较中,6种蛋白质(GDF15、ST2、MMP1、脂联素、瘦素、抵抗素)相关性好(r≥0.8),2种(骨桥蛋白和IL6)中等(0.5≤r<0.8),10种相关性差(r<0.5)。
  • SomaScan与靶向免疫分析的相关性根据病例状态相似。

关键数值与推荐

  • SomaScan与OLink平台间平均相关系数r=0.46(范围-0.21至0.97),79个(19%)比较r≥0.8。
  • SomaScan与靶向免疫分析比较中,6/18种蛋白质r≥0.8,2/18种0.5≤r<0.8,10/18种r<0.5。

临床怎么用

  • 在蛋白质定量研究中,应了解不同测量技术对每种蛋白质的变异,以指导研究设计和解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The plasma proteome can be quantified using different types of highly multiplexed technologies, including aptamer-based and proximity-extension immunoassay methods. There has been limited characterization of how these protein measurements correlate across platforms and with absolute measures from targeted immunoassays. METHODS: We assessed the comparability of (a) highly multiplexed aptamer-based (SomaScan v4; Somalogic) and proximity-extension immunoassay (OLINK Proseek® v5003; Olink) methods in 427 Atherosclerosis Risk in Communities (ARIC) Study participants (Visit 5, 2011-2013), and (b) 18 of the SomaScan protein measurements against targeted immunoassays in 110 participants (55 cardiovascular disease cases, 55 controls). We calculated Spearman correlations (r) between the different measurements and compared associations with case-control status. RESULTS: There were 417 protein comparisons (366 unique proteins) between the SomaScan and Olink platforms. The average correlation was r = 0.46 (range: -0.21 to 0.97; 79 [19%] with r ≥ 0.8). For the comparison of SomaScan and targeted immunoassays, 6 of 18 assays (growth differentiation factor 15 [GDF15], interleukin-1 receptor-like 1 [ST2], interstitial collagenase [MMP1], adiponectin, leptin, and resistin) had good correlations (r ≥ 0.8), 2 had modest correlations (0.5 ≤ r < 0.8; osteopontin and interleukin-6 [IL6]), and 10 were poorly correlated (r < 0.5; metalloproteinase inhibitor 1 [TIMP1], stromelysin-1 [MMP3], matrilysin [MMP7], C-C motif chemokine 2 [MCP1], interleukin-10 [IL10], vascular cell adhesion protein 1 [VCAM1], intercellular adhesion molecule 1 [ICAM1], interleukin-18 [IL18], tumor necrosis factor [TNFα], and visfatin) overall. Correlations for SomaScan and targeted immunoassays were similar according to case status. CONCLUSIONS: There is variation in the quantitative measurements for many proteins across aptamer-based and proximity-extension immunoassays (approximately 1/2 showing good or modest correlation and approximately 1/2 poor correlation) and also for correlations of these highly multiplexed technologies with targeted immunoassays. Design and interpretation of protein quantification studies should be informed by the variation across measurement techniques for each protein.

来源:Clin Chem,查看原文。版权归原作者所有。

引用

  1. Rooney MR, Chen J, Ballantyne CM, et al. Comparison of Proteomic Measurements Across Platforms in the Atherosclerosis Risk in Communities (ARIC) Study. Clin Chem. 2023. PMID: 36508319. doi:10.1093/clinchem/hvac186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。